UnknownNot Applicable

Predictive Value of Infarction Volume on Hemorrhagic Transformation in Ischemic Stroke/TIA With Non-valve Atrial Fibrillation(NVAF) Patients Using Rivaroxaban

China400 participantsStarted 2019-01-18

Plain-language summary

This study was aimed at patients with newly diagnosed stroke / TIA associated with nonvalvular atrial fibrillation. We will observe the effect of early using rivaroxaban anticoagulation on hemorrhagic transformation, and explore the predictive value of multi-mode MRI infarct volume / MMP-9 on hemorrhagic transformation after anticoagulation therapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male or female, age≥18;
✓. Were newly diagnosed asischemic stroke/TIA concomitant NVAF;
✓. Prescribedand accept Rivaroxaban;
✓. Sign thewritten informed consent.

Exclusion criteria

✕. Renal impairment (CrCl\<15 ml/min) or severe hepatic impairment.
✕. Significant hemorrhagic transformation (parenchymal hematoma type I or type II by the ECASS definition).
✕. Stroke or TIA caused by large artery atherosclerosis
✕. Planned major surgery or invasive intervention
✕. Active internal bleeding
✕. Malignancy or other serious medical conditions with a life expectancy \<6 months
✕. Allergery to Rivaroxaban
✕. Pregnancy or breast-feeding

What they're measuring

Susceptibility weighted imaging(SWI) detection of newly developed hemorrhagic transformation after 14 days of rivaroxaban treatment

Timeframe: 14 days after enrolling

Trial details

NCT IDNCT03772457

SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-12-31

Contact for this trial

Min Lou, PhD

13958007213 loumingxc@vip.sina.com

View on ClinicalTrials.gov More Cerebrovascular Stroke trials